
[0077] Example embodiment 50: A biodegradable intraocular implant comprising Compound 1:



Compound 1

substantially as described herein.

[0077a] Example embodiment 51: The biodegradable intraocular implant of example embodiments 1 to 32 for use in therapy.

BRIEF DESCRIPTION OF THE DRAWINGS

[0078] FIG. 1 shows a cross-section of the mammalian eye.

[0079] FIG. 2 shows the in vitro cumulative total percent release of Compound 1 into phosphate buffered saline (0.01 M; pH 7.4) at 37 °C. over time for six (6) separate implants (Implants 1-6). The composition of each implant is described in Table 2.

[0080] FIG. 3 shows the in vitro cumulative total percent release of Compound 1 into phosphate buffered saline (0.01 M; pH 7.4) at 37 °C. over time for Implants 1, 2 4, and 7. The composition of each implant is set forth in Table 2.

[0081] FIG. 4 shows the in vitro cumulative total percent release of Compound 1 into phosphate buffered saline (0.01 M; pH 7.4) at 37 °C. over time for Implants 1 and 5. The composition of each implant is set forth in Table 2.

[0082] FIG. 5 shows the in vitro daily release rate of Compound 1 into phosphate buffered saline (0.01 M; pH 7.4) at 37 °C. over time for Implants 1 and 5. The composition of each implant is set forth in Table 2.

[0083] FIG. 6 shows the in vitro cumulative total percent release of Compound 1 (API) in implants of R202H at different loadings (wt%) of Compound 1.